Leflunomide increases the risk of silent liver fibrosis in patients with rheumatoid arthritis receiving methotrexate

被引：0
|
作者：
Sang-Won Lee
Hee-Jin Park
Beom Kyung Kim
Kwang-Hyub Han
Soo-Kon Lee
Seung Up Kim
Yong-Beom Park
机构：
[1] Yonsei University College of Medicine,Department of Internal Medicine
[2] Yonsei University College of Medicine,Institute for Immunology and Immunological Diseases
[3] Yonsei University College of Medicine,Department of Medical Sciences
[4] Yonsei University College of Medicine,Institute of Gastroenterology
[5] Yonsei University College of Medicine,Liver Cirrhosis Clinical Research Center
来源：
Arthritis Research & Therapy | / 14卷
关键词：
Rheumatoid Arthritis; Rheumatoid Arthritis Patient; Chronic Liver Disease; Liver Fibrosis; Cumulative Dose;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [41] Serious liver disease in a patient receiving methotrexate and leflunomide
    Weinblatt, ME
    Dixon, JA
    Falchuk, KR
    ARTHRITIS AND RHEUMATISM, 2000, 43 (11): : 2609 - 2611
  • [42] Risk of liver fibrosis induced by methotrexate and other rheumatoid arthritis medications according to the Fibrosis-4 Index
    Avouac, J.
    Degrave, R.
    Vergneault, H.
    Combier, A.
    Wanono, S.
    Boisson, M.
    Frantz, C.
    Allanore, Y.
    CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 2022, 40 (01) : 150 - 157
  • [43] Pharmacoeconomic analisis of the treatment with leflunomide-methotrexate or infliximab-methotrexate in patients with rheumatoid arthritis resistant to methotrexate
    Terrés, RC
    Romero, F
    Burrell, A
    Domínguez-Gil, A
    VALUE IN HEALTH, 2002, 5 (06) : 475 - 475
  • [44] Comparison of Adverse Events and Survival of Treatment in Patients with Rheumatoid Arthritis Receiving Combined Treatment of Methotrexate and Leflunomide Versus Those Receiving Biological Therapy
    Cavalieri, Magdalena
    Rolon Campuzano, Roger
    Schneeberger, Emilce E.
    Dal Pra, Fernando
    Capelusnik, Dafne
    Ayelen Isnardi, Carolina
    Natalia Fornaro, Marina
    Citera, Gustavo
    ARTHRITIS & RHEUMATOLOGY, 2018, 70
  • [45] Benefit/risk of leflunomide in rheumatoid arthritis
    Kremer, JM
    Cannon, GW
    CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 2004, 22 (05) : S95 - S100
  • [46] Risk of hepatotoxicity with add-on leflunomide in rheumatoid arthritis patients
    Gupta, Rachna
    Bhatia, Jagriti
    Gupta, Suresh Kumar
    ARZNEIMITTEL-FORSCHUNG-DRUG RESEARCH, 2011, 61 (05): : 312 - 316
  • [47] A pragmatic non-invasive assessment of liver fibrosis in patients with psoriasis, rheumatoid arthritis or Crohn's disease receiving methotrexate therapy
    Cervoni, Jean-Paul
    Alby-Lepresle, Blandine
    Weil, Delphine
    Zhong, Peng
    Aubin, Francois
    Wendling, Daniel
    Toussirot, Eric
    Vuitton, Lucine
    Carbonnel, Franck
    Blondet, Raphaele
    Thevenot, Thierry
    Cales, Paul
    Monnet, Elisabeth
    Di Martino, Vincent
    CLINICS AND RESEARCH IN HEPATOLOGY AND GASTROENTEROLOGY, 2020, 44 : 100003
  • [48] Leflunomide increases the risk of early healing complications in patients with rheumatoid arthritis undergoing elective orthopedic surgery
    Martin Fuerst
    Henrike Möhl
    Kerstin Baumgärtel
    Wolfgang Rüther
    Rheumatology International, 2006, 26 : 1138 - 1142
  • [49] Leflunomide increases the risk of early healing complications in patients with rheumatoid arthritis undergoing elective orthopedic surgery
    Fuerst, Martin
    Moehl, Henrike
    Baumgaertel, Kerstin
    Ruether, Wolfgang
    RHEUMATOLOGY INTERNATIONAL, 2006, 26 (12) : 1138 - 1142
  • [50] Treatment of active rheumatoid arthritis with leflunomide compared with placebo and methotrexate
    Strand, V
    Cohen, S
    Schiff, M
    Weaver, A
    Fleischmann, R
    Cannon, G
    Fox, R
    Moreland, L
    Olsen, N
    Furst, D
    Caldwell, J
    Kaine, J
    Sharp, J
    Hurley, F
    Loew-Friedrich, I
    ARCHIVES OF INTERNAL MEDICINE, 1999, 159 (21) : 2542 - 2550
12345